Biden Administration Rescinds Trump Administration Insulin …
WEBOct 26, 2021 · One of the final healthcare actions made by the Trump Administration has been rescinded by the Biden Administration. On December 23, 2020, the Trump Administration finalized a rule that directed the Department of Health and Human Services (HHS) to take action to require that federally qualified health centers (FQHCs) make insulin and injectable epinephrine available to certain patients at 340B ...
New York is the Latest State to Allow Full Practice Authority for …
WEBMay 25, 2022 · On April 11, 2022, New York Governor Kathy Hochul signed the state budget into law, which includes reforms surrounding services that health care workers are allowed to provide and will allow nurse practitioners full practice authority.New York joined with 24 other states, the District of Columbia, and two United States territories in adopting full practice authority legislation.
Institute of Medicine Report – The Future of Nursing: Leading …
WEBFeb 17, 2011 · As the current debate surrounding the Affordable Care Act (ACA) continues in Congress, a number of strengths and weaknesses of the legislation are being emphasized. One specific issue is how the American …
ACA Section 1557: A Comprehensive Overview for Healthcare …
WEBJul 10, 2024 · The 2024 final rule for ACA Section 1557 represents a significant step forward in promoting non-discrimination in healthcare. While the new requirements pose challenges for healthcare providers, they also offer an opportunity to improve access and equity in healthcare services. The Medical Society of …
PhRMA Announces Updated Code on Interactions with Health …
WEBOn August 6, 2021, the Pharmaceutical Research and Manufacturers of America (PhRMA) released its updated Code on Interactions with Health Care Professionals, a voluntary code of ethics that applies to pharmaceutical company interactions with United States health care professionals. As a member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the PhRMA ...
Policy & Medicine – Legal, Regulatory, and Compliance Issues
WEBIn today's healthcare environment, physicians face numerous challenges that significantly impact their professional lives and personal well-being. Among these, the complexities of electronic medical records (EMRs) and the pervasive issue of burnout are particularly significant. This article delves into how these elements influence the daily….
CMS Updates Guidance on Sunshine Act Reporting Thresholds for …
WEBJan 25, 2021 · At the end of 2020, the Centers for Medicare and Medicaid Services (CMS) issued updated guidance on the thresholds that require an Applicable Manufacturer or Group Purchasing Organization to report under the Sunshine Act. Under the new guidance, if an Applicable Manufacturer or Group Purchasing Organization spends $11.05 or more on a “Reportable Activity” for any Covered Recipient from ...
CMS Releases Additional Information about the Cell and Gene …
WEBApr 1, 2024 · The Centers for Medicare and Medicaid Innovation (CMMI) previously released three new payment models, all aimed at lowering drug costs. One of those models, the Cell and Gene Therapy (CGT) Access Model, has now been developed and greater detail provided about what to expect.The CGT Access Model will focus on improving health outcomes for Medicaid beneficiaries who could benefit from cell and ...
Pharmacists’ Role to Expand Over the Next Decade
WEBMar 23, 2022 · According to recent research from the Columbia University Mailman School of Public Health and Express Scripts Pharmacy, pharmacists are well-trusted by patients and are expected to play an “increasingly integral role in care management.” The research surveyed more than 3,000 patients, 1,000 pharmacists, and 500 medical providers, and was designed to get a better understanding of the ...
Connecticut’s New Drug Pricing Law Requires ... - Policy & Medicine
WEBJun 5, 2018 · On May 31 st, Connecticut’s governor Daniel Malloy signed into law Substitute House Bill 5384, which imposes cost disclosure and reporting requirements on pharmacy benefit managers (PBMs), health carriers, and pharmaceutical manufacturers (now, Public Act No. 18-41).. A summary of the law is provided below and partially taken from the Office of Legislative Research analysis.